RT Journal Article
T1 Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
A1 Luczkowiak, Joanna
A1 Rivas, Gonzalo
A1 Labiod, Nuria
A1 Lasala, Fátima
A1 Rolo, Marta
A1 Lora-Tamayo Morillo-Velarde, Jaime
A1 Mancheno Losa, Mikel
A1 Rial Crestelo, David
A1 Pérez Rivilla, José Alfredo
A1 Folgueira López, María Dolores
A1 Delgado Vázquez, Rafael
AB We have measured the humoral response to messenger RNA (mRNA) vaccines in COVID-19 naïve and convalescent individuals. Third doses of mRNA COVID-19 vaccines induced a significant increase in potency and breadth of neutralization against SARS-CoV-2 variants of concern (VoC) including Omicron subvariants BA.1, BA.2, and BA.2.12.1, that were cross-neutralized at comparable levels and less for BA.4/5. This booster effect was especially important in naïve individuals that only after the third dose achieved a level that was comparable with that of vaccinated COVID-19 convalescents except for BA.4/5. Avidity of RBD-binding antibodies was also significantly increased in naïve individuals after the third dose, indicating an association between affinity maturation and cross neutralization of VoC. These results suggest that at least three antigenic stimuli by infection or vaccination with ancestral SARS-CoV-2 sequences are required to induce high avidity cross-neutralizing antibodies. Nevertheless, the circulation of new subvariants such as BA.4/5 with partial resistance to neutralization will have to be closely monitored and eventually consider for future vaccine developments.
PB Wiley
SN 0146-6615
YR 2023
FD 2023-11-01
LK https://hdl.handle.net/20.500.14352/72699
UL https://hdl.handle.net/20.500.14352/72699
LA eng
NO CRUE-CSIC (Acuerdos Transformativos 2022)
NO Union Europea. Horizonte Europa
NO Unión Europea. Horizonte 2020
NO Instituto de Salud Carlos III (ISCIII)
NO Fundación Caixa‐Health Research
DS Docta Complutense
RD 9 abr 2025